RxDoctor Payments DataLook up a doctor →

Walter Chatham

Rheumatology · Las Vegas, NVNPI 1154363315

Payments from drug & device makers

$2,208,359in general payments, 2019–2025

Across 453 payments — averaging $4874.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$452K
  • GSK$337K
  • E.r. Squibb & Sons, L.L.C.$269K
  • Amgen$229K
  • Astrazeneca UK Limited$176K
  • Janssen Research & Development, LLC$167K
  • plus $579K from 30 others
$1,471in research payments, 2019–2025

Across 2 payments — averaging $735.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,208,359 in reported general payments places this provider in the 95th percentile of 43 rheumatology providers in Nevada.

See all rheumatology providers in Nevada

Medicare billing

Part B allowed, 2024
$23,412
Medicare patients
88
Services billed
213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →